150 related articles for article (PubMed ID: 37405030)
1. A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib.
Kimura S; Fujisaki Y; Onizuka C; Hasuike S; Sato Y; Mukai S; Kamoto T
IJU Case Rep; 2023 Jul; 6(4):206-210. PubMed ID: 37405030
[TBL] [Abstract][Full Text] [Related]
2. Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib.
Airò G; Maffezzoli M; Lazzarin A; Bianconcini M; Greco A; Buti S; Leonetti A
Immunotherapy; 2022 Nov; 14(16):1297-1305. PubMed ID: 36408614
[TBL] [Abstract][Full Text] [Related]
3. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto K; Shirotake S; Miyama Y; Kaneko G; Kanao K; Igarashi D; Takahashi T; Umezawa Y; Yasuda M; Oyama M
IJU Case Rep; 2022 May; 5(3):149-152. PubMed ID: 35509782
[TBL] [Abstract][Full Text] [Related]
4. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment.
Takayama K; Numakura K; Igarashi R; Habuchi T
IJU Case Rep; 2022 Nov; 5(6):517-520. PubMed ID: 36341192
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
7. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
[TBL] [Abstract][Full Text] [Related]
8. Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis.
Imai S; Nakamura M; Chujo S; Ooki R; Inoue Y; Horiuchi H; Morikawa T; Uchino K; Igarashi A; Shiga Y
IJU Case Rep; 2021 Nov; 4(6):386-390. PubMed ID: 34755064
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.
Tamada S; Ikarashi D; Tsuyukubo T; Iwasaki K; Isurugi K; Ono S; Takata R; Fujisawa H; Obara W
IJU Case Rep; 2022 Nov; 5(6):438-441. PubMed ID: 36341193
[TBL] [Abstract][Full Text] [Related]
10. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.
Dulgar O; Cil I; Zirtiloglu A; Tural D
J Oncol Pharm Pract; 2019 Sep; 25(6):1512-1515. PubMed ID: 30058939
[TBL] [Abstract][Full Text] [Related]
14. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.
Hanawa K; Sawada N; Aikawa J; Otake Y; Kasai Y; Mochizuki K; Shimura H; Mochizuki T; Kira S; Mitsui T
Oncol Lett; 2024 Feb; 27(2):66. PubMed ID: 38192652
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W
Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
19. Axitinib in Metastatic Renal Cell Carcinoma.
Mittal K; Wood LS; Rini BI
Biol Ther; 2012; 2(1):5. PubMed ID: 24392298
[TBL] [Abstract][Full Text] [Related]
20. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C
Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
